If You Invested in Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is a biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, Intra-Cellular Therapies is focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The company states that it is founded on Nobel Prize-winning research that helps explain how therapies affect the inner workings of cells, and it applies this intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases.

Core business and therapeutic focus

Intra-Cellular Therapies describes itself as a CNS-focused biopharmaceutical company. Its business centers on researching, developing, and commercializing medicines that target psychiatric and neurologic conditions. The company highlights that its work is grounded in Nobel Prize-winning science related to intracellular signaling, and it uses this scientific foundation to design and advance drug candidates intended to address serious mental health and neurologic disorders.

A key commercial product for Intra-Cellular Therapies is CAPLYTA (lumateperone). Company communications state that CAPLYTA 42 mg is an oral, once-daily atypical antipsychotic approved in adults for the treatment of schizophrenia and for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The company notes that while the mechanism of action of CAPLYTA is unknown, its efficacy could be mediated through antagonist activity at central serotonin 5‑HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.

Research and development programs

Intra-Cellular Therapies reports that it is advancing a pipeline of CNS-focused programs. Lumateperone, the active ingredient in CAPLYTA, is being studied for additional indications beyond its approved uses. Company updates state that lumateperone is being evaluated as an adjunctive treatment for major depressive disorder (MDD) in adults. Two positive Phase 3 global, double-blind, placebo-controlled studies (Studies 501 and 502) in patients with MDD who had an inadequate response to ongoing antidepressant therapy form the basis of a supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) for this adjunctive MDD indication.

The company has also described additional lumateperone clinical programs, including studies in bipolar disorder and schizophrenia populations and pediatric programs. According to its updates, lumateperone is being studied in bipolar I disorder with manic or mixed episodes, in pediatric patients with bipolar depression and schizophrenia, and in pediatric patients for the treatment of irritability associated with autism spectrum disorder. Intra-Cellular Therapies also reports that lumateperone is being evaluated in adults for the acute treatment of manic or mixed episodes associated with bipolar I disorder and in long-term safety studies.

Beyond lumateperone, Intra-Cellular Therapies highlights several other pipeline programs. The ITI-1284-ODT-SL program is being studied in Phase 2 clinical trials in patients with generalized anxiety disorder (GAD), both as adjunctive therapy to approved GAD medications and as monotherapy, and in patients with psychosis associated with Alzheimer’s disease and in agitation associated with Alzheimer’s disease. The company also references a phosphodiesterase type I (PDE1) inhibitor program, including lenrispodun (ITI-214) in a Phase 2 study in Parkinson’s disease and ITI-1020 in oncology indications. In addition, Intra-Cellular Therapies describes an ITI-1500 non-hallucinogenic neuroplastogen program, with ITI-1549 advancing through investigational new drug (IND) enabling studies.

Commercial product: CAPLYTA (lumateperone)

Company materials identify CAPLYTA as a central product. CAPLYTA is described as an oral, once-daily atypical antipsychotic available in 10.5 mg, 21 mg, and 42 mg capsules. It is indicated in adults for the treatment of schizophrenia and for depressive episodes associated with bipolar I or II disorder as monotherapy and as adjunctive therapy with lithium or valproate. Intra-Cellular Therapies reports that CAPLYTA’s clinical data show efficacy in these indications and that its safety and tolerability profile has been characterized in multiple studies, including short-term and maintenance trials.

Intra-Cellular Therapies has reported financial results that reflect net product sales of CAPLYTA and associated operating expenses. The company attributes increases in selling, general and administrative expenses to commercialization, marketing, and infrastructure costs, and increases in research and development expenses to lumateperone and non-lumateperone project costs, including the ITI‑1284, ITI‑214, and ITI‑1500 programs.

Corporate developments and pending acquisition

Intra-Cellular Therapies has announced that it entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies. According to the joint announcement, Johnson & Johnson and Intra-Cellular Therapies agreed on a cash transaction in which Johnson & Johnson will acquire the company for a stated per-share price and total equity value. The companies state that, following completion of the transaction and subject to regulatory approvals, stockholder approval, and other customary closing conditions, Intra-Cellular Therapies’ common stock will no longer be listed for trading on the Nasdaq Global Select Market.

Under this agreement, Johnson & Johnson will add CAPLYTA (lumateperone) and Intra-Cellular Therapies’ pipeline programs, including ITI-1284 and PDE1 inhibitors, to its Innovative Medicine business. The transaction is described as part of Johnson & Johnson’s strategy to strengthen its neuroscience portfolio. Until the transaction closes, Intra-Cellular Therapies continues to be described as a Nasdaq-listed biopharmaceutical company operating under the symbol ITCI.

Intellectual property and legal matters

Intra-Cellular Therapies has disclosed patent litigation related to CAPLYTA. The company announced a settlement agreement with Sandoz Inc. resolving litigation that arose from Sandoz’s submission of an Abbreviated New Drug Application (ANDA) seeking approval to market a generic equivalent of CAPLYTA in the United States. Under the settlement, Intra-Cellular Therapies states that Sandoz is permitted to begin selling generic versions of CAPLYTA on a specified future date or earlier under certain circumstances. The company notes that similar patent litigation with other parties remains pending.

Scientific foundation and therapeutic areas

Across its public communications, Intra-Cellular Therapies emphasizes that it is founded on Nobel Prize-winning research into intracellular mechanisms. The company explains that this research underpins its understanding of how therapies affect cellular processes in the body and guides the design of its CNS-focused drug candidates. Its stated goal is to develop treatments for complex psychiatric and neurologic diseases, including schizophrenia, bipolar depression, major depressive disorder, generalized anxiety disorder, Alzheimer’s disease-related psychosis and agitation, Parkinson’s disease, and oncology indications associated with its PDE1 program.

Through CAPLYTA and its pipeline, Intra-Cellular Therapies positions itself as a developer and commercializer of CNS therapeutics that are informed by intracellular biology. Its disclosures highlight ongoing late-stage clinical trials, supplemental regulatory submissions, and collaborations with regulators and scientific communities through conference presentations and data releases.

ITCI stock and sector classification

ITCI is the ticker symbol for Intra-Cellular Therapies on the Nasdaq Global Select Market. Within broad industry classifications, the company is associated with pharmaceutical preparation manufacturing and the manufacturing sector, with a specific focus on biopharmaceutical research and commercialization in central nervous system disorders.

Frequently asked questions about Intra-Cellular Therapies (ITCI)

• What does Intra-Cellular Therapies do?
  Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. It states that its work is based on Nobel Prize-winning research into how therapies affect the inner workings of cells, and it applies this science to create treatments for complex psychiatric and neurologic diseases.
• What is CAPLYTA (lumateperone)?
  CAPLYTA (lumateperone) is an oral, once-daily atypical antipsychotic developed and commercialized by Intra-Cellular Therapies. According to the company, CAPLYTA 42 mg is approved in adults for the treatment of schizophrenia and for depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.
• How is lumateperone being studied beyond its approved uses?
  Intra-Cellular Therapies reports that lumateperone is being studied for the treatment of major depressive disorder (MDD) as adjunctive therapy to antidepressants and in other psychiatric and neurologic disorders. Two positive Phase 3 studies (Studies 501 and 502) in MDD form the basis of a supplemental New Drug Application submitted to the FDA for adjunctive treatment of MDD.
• What other pipeline programs does Intra-Cellular Therapies highlight?
  The company describes several programs, including the ITI-1284-ODT-SL program in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation, a PDE1 inhibitor program with lenrispodun (ITI-214) in Parkinson’s disease and ITI-1020 in oncology indications, and the ITI-1500 non-hallucinogenic neuroplastogen program with ITI-1549 in IND-enabling studies.
• What therapeutic areas does Intra-Cellular Therapies focus on?
  Intra-Cellular Therapies states that it focuses on central nervous system disorders, including schizophrenia, bipolar depression, major depressive disorder, generalized anxiety disorder, Alzheimer’s disease-related psychosis and agitation, Parkinson’s disease, and certain oncology-related indications within its PDE1 program.
• How does Intra-Cellular Therapies describe the science behind its drugs?
  The company explains that it is founded on Nobel Prize-winning research that clarifies how therapies affect intracellular processes. It uses this intracellular approach to design and develop treatments aimed at complex psychiatric and neurologic diseases.
• What is the status of Johnson & Johnson’s acquisition of Intra-Cellular Therapies?
  Johnson & Johnson and Intra-Cellular Therapies have announced a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for cash, subject to regulatory approvals, approval by Intra-Cellular Therapies’ stockholders, and other customary closing conditions. The companies state that, following completion of the transaction, Intra-Cellular Therapies’ common stock will no longer be listed on the Nasdaq Global Select Market.
• What did the company disclose about CAPLYTA-related patent litigation?
  Intra-Cellular Therapies announced a settlement agreement with Sandoz Inc. resolving patent litigation related to CAPLYTA. The company states that the settlement permits Sandoz to begin selling generic versions of CAPLYTA on a specified future date or earlier under certain circumstances, and that similar patent litigation with other parties remains pending.
• How does Intra-Cellular Therapies describe CAPLYTA’s safety profile?
  Company communications summarize that the most common adverse reactions in clinical trials with CAPLYTA versus placebo include somnolence or sedation, dizziness, nausea, and dry mouth. They also describe boxed warnings and precautions typical for antipsychotic drugs, including risks related to elderly patients with dementia-related psychosis and antidepressant-associated suicidal thoughts and behaviors in certain populations.
• What sector and industry is ITCI associated with?
  Based on available classifications, ITCI is associated with the pharmaceutical preparation manufacturing industry within the broader manufacturing sector, with a specific focus on biopharmaceutical products for central nervous system disorders.